Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Deleterious BRCA-mutated or HRD-positive Ovarian, Breast, Pancreatic, and Prostate Cancers.
HR-positive Breast Cancer in adjuvant, metastatic, and chemoprevention settings.
EGFR-mutated Non-Small Cell Lung Cancer (NSCLC).
Approved for use in oncology care according to FDA-approved indications.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Ph+ Acute Lymphoblastic Leukemia (ALL).
Advanced solid tumors and hematologic malignancies with matching genomic alterations.
Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Kaposi Sarcoma, and Lymphomas.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.